Table 3.
Clinical and biochemical characteristics of the Kazakh study cohorts matched for age
| Control subjects | Type 2 diabetic subjects | P-value | |
|---|---|---|---|
| N | 141 | 223 | |
| Male,% (n) | 41,1% (58) | 46,6% (104) | 0.39 |
| Age, years | 52 (43–61) | 53 (40–63) | 0.11 |
| Weight, kg | 72 (47–125) | 82 (46–135) | <10−5 |
| Height, cm | 165 (140–192) | 166 (148–188) | 0.31 |
| BMI, kg/m2 | 26.56 (17.2–43.1) | 29.74 (18.4–47.2) | <10−5 |
| Systolic blood pressure, mm Hg | 120 (90–140) | 130.0 (100–220) | <10−5 |
| Diastolic blood pressure, mm Hg | 80 (60–90) | 80 (60–130) | <10−5 |
| Waist circumference, cm | 89 (60–180) | 94 (60–160) | 0.01 |
| Hip circumference, cm | - | 100 (63–165) | - |
| Waist/hip ratio | - | 0.95 (0.54–1.83) | - |
| Glucose, mmol/L | 5.15 (3.8–6.5) | 9.2 (4.1–30.5) | <10−5 |
| Cholesterol, mmol/L | 4.9 (2.4–11.8) | 5.2 (2.8–16.7) | 0.12 |
| Triglycerides, mmol/L | 1.2 (0.4–3.8) | 1.9 (0.2–17.6) | <10−5 |
| Low-density lipoproteins, mmol/L | 4.57 (1.78–15.50) | 4.71 (1.56–8.67) | 0.47 |
| High-density lipoproteins, mmol/L | 1.32 (0.7–2.8) | 1.23 (0.62–3.6) | 0.009 |
| HbA1c, % | 5.9 (4.5–6.7) | 7.65 (4.4–16.4) | <10−5 |
| Insulin, μIU/mL | - | 12.70 (0.02–97.0) | - |
| C-peptide, ng/mL | - | 4.20 (0.14–12.0) | - |
Data are expressed as median (range) unless otherwise specified